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Summary 
Background: Various in vivo and in vitro models have been
described in order to elucidate the pathobiology underlying
the traumatic brain injury (TBI) and test potentially suitable
treatments. Since TBI is a complex disease, models differ in
regard to the aspect of TBI that is being investigated. One of
the used in vitro models is the scratch wound assay, first
established as a reproducible, low-cost assay for the analysis
of cell migration in vitro. The aim of the present study was to
further investigate the relevancy of this model as a counter-
part of in vivo TBI models. 
Methods: We have examined the astrocytic response to a
mechanical injury in terms of expression of chondroitin sul-
fate proteoglycans (CSPGs) – phosphacan, neurocan and
brevican, using real-time PCR and immunocytochemistry.
Results: Our results indicate that in vitro scratch wounding
alters the expression profile of examined CSPGs. Four hours
after the scratch injury of the astrocytic monolayer, real-time
PCR analysis revealed upregulation of mRNA levels for phos-
phacan (3-fold) and neurocan (2-fold), whereas brevican
mRNA was downregulated (2-fold). Immunofluorescent sig-
nal for phosphacan and neurocan was more intense in astro-
cytes close to the injury site, while brevican was scarcely
present in cultured astrocytes. 
Conclusions: Obtained results indicate that CSPGs are differ-
entially expressed by astrocytes after scratch wounding,
Kratak sadr`aj
Uvod: Brojni in vivo i in vitro modeli opisani su sa ciljem da
se rasvetle patobiolo{ki procesi koji su osnova traumatske
povrede mozga (TPM) i testiraju potencijalni tretmani.
Imaju}i u vidu da je TPM kompleksno oboljenje, ovi mode li
se me|usobno razlikuju shodno aspektu TPM koji se ispitu-
je. Jedan od in vitro modela je i povreda }elijskog jednoslo-
ja grebanjem (engl. »scratch wound« assay), isprva usta nov -
 ljen kao ponovljiv, jeftin test za analizu }elijske migracije in
vitro. Cilj ove studije je da se bli`e ispita relevantnost ovog
modela u odnosu na in vivo modele TPM. 
Metode: Da bi se istra`io odgovor astrocita na mehani~ku
povredu, pra}ena je ekspresija odabranih hondroitin-sulfatnih
proteoglikana (CSPG) – fosfakana, neurokana i brevi kana,
ko ri{}enjem PCR u realnom vremenu i imunocitohemije. 
Rezultati: Dobijeni rezultati su pokazali da in vitro povreda
astro citnog jednosloja menja profile ekspresije ispitivanih
CSPG. ^etiri sata nakon povrede, primena PCR u realnom
vremenu analize pokazala je pove}anje nivoa iRNK za fos-
fakan (trostruko) i neurokan (dvostruko), dok je iRNK za
brevikan bila smanjena na polovinu kontrolne vrednosti.
Imunofluorescentni signal poreklom od fosfakana i neuro -
kana je bio intenzivniji u astrocitima bli`im mestu povrede,
dok je signal za brevikan bio slab kako u kontrolnoj, tako i
u ozle|enoj grupi. 
Zaklju~ak: Dobijeni rezultati pokazuju da povreda izazvana
grebanjem razli~ito uti~e na ekspresiju ispitivanih CSPG u
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Introduction
Traumatic brain injury (TBI) is a leading cause of
death and disability and a major health burden world-
wide. It is generally accepted that TBI is a complex,
biphasic disease consisting of primary and secondary
injury. Primary injury is an immediate damage that
triggers a secondary injury, which affects the brain to
a greater extent, causing delayed neuronal death and
neurological deficits (1). Although there is a large
database of knowledge regarding processes which
take place after TBI, to date no successful treatment
has been defined, indicating that there is clearly a
need for further studies of TBI (2, 3). In the founda-
tions of this need, there is an urge to define appropri-
ate models of TBI, both in vivo and in vitro. 
Different in vivo models of TBI have been des -
cribed so far and used in order to examine the back -
ground of TBI. Since the primary insult cannot be
therapeutically approached, in vivo models are orien-
tated toward examination and treatments of second-
ary damage, which is substantially recognized through
a process of reactive astrogliosis. The hallmark of
reactive astrogliosis is the formation of a glial scar, a
barrier to axonal regeneration (4). Beside mentioned,
the upregulation of several proteins, including chon-
droitin sulfate proteoglycans (CSPG) is reported as
well (5–7). In the adult brain, basic levels of CSPGs are
necessary, since they maintain the structure of extra-
cellular matrix (ECM), stabilize synapse and proper
axonal sprouting, and therefore manage plasticity (8,
9). It is believed that all of the major brain cell types
contribute to the production of these normal levels of
CSPG (9). However, in pathological conditions, upre -
gulation of CSPG occurs and it is mainly attributed to
astrocyte activation (10). 
A number of in vitro models have been intro-
duced in order to reproduce the features of interest in
an isolated system and to allow manipulations, moni-
toring on multiple levels in real time, while being pre-
cisely controlled (11, 12). One of such is a scratch-
wound assay (SW), first established as a simple,
reproducible assay for the analysis of cell migration in
vitro (13). The SW model was soon adopted by many
to investigate different aspects of astroglial response
to mechanical injury (14–17). As a response to SW
injury, the following characteristics of reactive astro-
cytes have been observed: hyperplasia, enhanced
expression of extracellular matrix molecules and elon-
gation of hypertrophic processes (18, 19). 
The aim of the present study was to further
describe astrocyte response in an SW model, in re gard
to alterations in expression of CSPGs after scratch
wounding in vitro. Therefore, using quantitative real-
time PCR and immunohistochemistry, we have inves-
tigated the expression profiles of phosphacan, neuro-
can and brevican. 
Material and Methods
The mixed astrocyte and microglia culture was
prepared from Wistar pups up to 3 days postpartum
obtained from the vivarium of the Institute for Bio -
logical Research »Sini{a Stankovi}« (Belgrade, Ser -
bia). All experimental procedures were in compliance
with the EEC Directive (86/609/EEC) on the protec-
tion of animals used for experimental and other scien-
tific purposes, and were approved by the Ethical
Committee for the Use of Laboratory Animals of the
Institute for Biological Research »Sini{a Stankovi}«,
University of Belgrade.
Cell culture
The preparation of mixed astrocyte and micro -
glia culture was done as described previously
(McCarthy & De Vellis, 1980). The cultures were kept
in Dulbecco’s Modified Eagle’s Medium, (DMEM,
Gibco, InvitrogenCo, Carlsbas, CA, USA) supple-
mented with 10% FCS (PAA Laboratories GmbH,
Aus tria) and 1% penicillin/streptomycin (PAA La bo -
ratories GmbH, Austria). The medium was changed
every 2–3 days. After 10–14 days, extent of micro -
glial cells was detached from the astrocytes and
remaining cells were then pelleted by centrifugation
(3000 rpm for 5 min). For immunocytochemical
(ICC) and morphological analysis, cells were plated at
6×105 on glass cover slip circles (25 mm) in 6-well
plates (Sarstedt, Newton, USA) with 2 mL DMEM
with 10% FCS per well. Twenty-four hours before the
in duction of scratch wound, medium was changed
with DMEM containing 0.1% FCS. Scratch wound
assay was performed as previously described (17).
Briefly, confluent cell monolayers were wounded by
scratching with a sterile pipette (yellow) tip, inducing
three (for qRT-PCR analysis) or two (for ICC analysis)
parallel scratches per well. The number of microglial
cells and astrocytes in each culture was evaluated by
double immunofluorescence staining against IBA1
(Se ro tec, mouse, 1:400) and GFAP (DAKO Cytoma -
tion, rabbit, 1:700).
demonstrating that the scratch wound model might be suit-
able for investigation of astrocyte-derived response to injury.
Keywords: reactive astrocytes, chondroitin sulfate proteo-
glycans, in vitro model, scratch-wound assay, gene expres-
sion
astrocitima, {to ukazuju da ovaj model mo`e biti pogodan
za ispitivanje odgovora astrocita na povredu.
Klju~ne re~i: reaktivni astrociti, hondroitin-sulfatni pro-
teoglikani, in vitro model, »scratch-wound« test, ekspresija
gena
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Real-time PCR analysis 
For RNA extracts, 8x106 cells were plated in six-
well plates (Sarstedt, Newton, USA). Total RNA was
isolated using the PeqGold RNA Pure reagent
(Peqlab, Biotechnologie GmbH, Erlangen, Germany)
according to the manufacturer’s recommended pro-
tocol. RNA was reverse transcribed to cDNA using the
High-Capacity cDNA Reverse Transcription Kit (App -
lied Biosystems, Carlsbad, CA, USA). Quantitative
real-time PCR (qRT-PCR) was conducted using SYBR
Green technology (Applied Biosystems, Carlsbad, CA,
USA) and analyzed on an AbiPrism 7000 (Applied
Bio systems, Carlsbad, CA, USA). Primer pairs for
phos phacan, neurocan, brevican and cyclophilin-A
were from Invitrogen, Germany (Table I). The target
gene expression levels were determined by the com-
parative 2^ (-delta Ct) quantification method using
cyclo philin-A as a reference gene.
Phase-contrast microscopy and 
immunocytochemical (ICC) analysis
Phase-contrast and ICC analyses were perfor -
med using standard protocol. Live cells were used for
phase-contrast imaging, at different time points after
scratch injury. Briefly, for ICC analyses, cells were
fixed for 20 min in 4% paraformaldehyde (PFA) at 4
°C. Permeabilization was performed in 0.25% Triton
X – 100 for 10 min, followed by blocking of nonspe-
cific staining in 1% BSA for 30 min. Double labeling
procedure was performed with the following primary
antibodies: anti-IBA1 (Abcam, Cambridge, MA, USA,
goat, 1:500), anti-phosphacan (Chemicon, mouse,
1:400), anti-neurocan (Santa Cruz, mouse, 1:400),
and anti-brevican (Santa Cruz Biotechnology, Santa
Cruz, CA, USA, goat, 1:400) with anti-GFAP (DAKO
Cytomation, Denmark, rabbit, 1:700), overnight at
4 °C. Visualization of reaction was obtained using
appropriate secondary fluorescent antibodies (1:250,
Alexa Fluor 488 goat anti-mouse, Alexa Fluor 488
donkey anti-goat, and Alexa Fluor 555 donkey anti-
rabbit, Invitrogen, Grand Island, NY, USA) and
nuclei were marked using DAPI (Invitrogen, Grand
Island, NY, USA). The cells were cover-slipped with
Mowiol (Calbiochem, San Diego, CA, USA). To test
the specificity of the reaction, cell cultures were treat-
ed in the same way with the omission of the primary
antibodies. Phase-contrast imaging and immu no -
fluorescence were examined and photo graphed with
Carl Zeiss Axiovert microscope (Zeiss, Gottin gen,
Germany). Cell count for astrocyte/microglia ratio
was performed in seven quadrants (0.38 mm2) per
each specimen from three independent experiments
(n=21).
Statistical analysis
Data obtained with qRT-PCR analysis are shown
as means ± SEM. Statistical significance of dif fe -
rences between the groups was determined using the
one-way analysis of variance (ANOVA for repeated
measures) whereas P values less than 0.05 (p<0.05)
were considered statistically significant. 
Results
General characteristics of the SW model and
mixed glial cell culture
Astrocytic monolayer was examined up to 48
hours after the SW (for schematic representation, see
Figure 1A), using phase-contrast microscopy (Figure
1B). These results showed the characteristic morpho-
logical features and migration trend of astrocytes at
the injury site in the given time points (4, 24 and 48
hours after the SW). In order to determine the ratio
of astrocyte/microglia in mixed glial culture, staining
with IBA1 and GFAP was performed (Figure 1C).
Results indicated that this ratio is approximately 9:1 in
favor of astrocytes (Figure 1D). 
Real-time PCR analysis of CSPGs expression 
profiles in cultured astrocytes before and after SW
Gene expression analysis showed that all three
proteoglycans analyzed herein are expressed in mixed
astrocyte-microglia culture (Figure 2). However, the
results showed that there is a distinct difference in
abundance of neurocan, phosphacan and brevican
mRNAs when expressed relative to cyclophilin-A.
Neurocan-mRNA was 2 times more abundant than
phosphacan-mRNA and 14 times more abundant
than brevican-mRNA. The qRT-PCR results also
demonstrated that GFAP mRNA content remained
unchanged after the SW. Four hours following the SW,
both phosphacan and neurocan mRNAs were signifi-
cantly upregulated (2.73±0.66, 5.2±1.2, respec-
tively) when compared to the control group (0.94±
0.27, 2.2±0.76, respectively, P<0.05). In contrast,
the level of brevican mRNA dropped considerably
(0.08±0.007) below the control values (0.17±0.11,
P<0.05). 
Primer Sequence
Cyclophilin-A Forward – GGCAAATGCTGGACCAAACAC
Reverse – TTAGAGTTGTCCACAGTCGGAGATG
GFAP Forward – CTCCTATGCCTCCTCCGAGACGAT
Reverse –  GCTCGCTGGCCCGAGTCTCTT
Brevican Forward – CCTCAGGAAGCTGTGGAGAG
Reverse –  CTTGCCCCATCTGGAGTAGA
Phosphacan Forward – TTGACAAGTGATGAAGAGAGTGG
Reverse – AATCAGCACATCTCGTTCTATCC
Neurocan Forward – TTTCAGTCCACAGCGATCAG
Reverse –  AGGAGAGGGATACAGCAGCA
Table I List of primers used for real-time polymerase chain
reaction.
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Effect of SW on neurocan, phosphacan and
brevican immunosignal in cultured astrocytes
To further depict the expression of neurocan,
phosphacan and brevican after the SW at a given time
point, double immunofluorescence analysis together
with DAPI fluorescence counter-labeling was per-
formed (Figure 3, injury site is marked with a dashed
line). In control samples, phosphacan and neurocan
were occasionally detected in the cytosol of GFAP po -
sitive astrocytes (Figure 3A-D, I-L). Consistent with low
mRNA expression, brevican was scarcely present in
some astrocytes in control samples (Figure 3Q-T).
Immu no fluorescent signal for phosphacan and neuro-
can was enhanced four hours after the SW, and inten-
sive labeling was seen in the majority of astrocytes sur-
rounding the injury site (Figure 3E-H, M-P). At the
same time point, no difference in immunofluorescent
intensity was seen for brevican (Figure 3U-X).
Discussion
Although in vitro models of TBI cannot be con-
sidered a substitute for in vivo models, they are
Figure 1 General characteristics of SW model and mixed glial cell culture. 
(A) Schematic preview of SW injury. (B) Phase-contrast imaging at 4, 24 and 48 hours after the injury revealed the expected astro -
cytic response to scratch. Injury site is marked with an asterisk. (C) Participation of astrocytes and microglia in mixed glial cell culture
is determined by double immunofluorescence staining for GFAP (red) and IBA1 (green), respectively. Nuclei are stained with DAPI
(blue). Scale bar: 30 mm. (D) Astro cytes/microglia ratio was approximately 9:1 (n=21).
Figure 2 The effect of SW on GFAP, phosphacan, neuro-
can and brevican mRNA expression determined by qRT-
PCR. Levels of each CSPGs mRNA were expressed relative
to the expression of cyclophilin-A used as a housekeeping
gene. Proteoglycans mRNA relative expression values four
hours after the scratch wound (SW 4h) were compared to
corresponding control groups (C 4h) and presented as
mean ± SEM. The values of *P<0.05 were considered
statistically significant.
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Figure 3 Double immunofluorescence staining of phosphacan, neurocan and brevican (green) and GFAP (red). Nuclei in
overlapped images are marked with DAPI (blue). In control groups phosphacan and neurocan immunofluorescence were
detected in cytosol of some astrocytes (A-D, I-L, arrows), while brevican was scarcely present (Q-T, arrows). At SW 4h, most of
the astrocytes close to the injury site were stained positive for phosphacan and neurocan (E-H, M-P, arrows). Compared to con-
trol, brevican immunofluorescence staining was slightly changed at SW 4h (U-X, arrows). SW site is marked with a dashed line.
Scale bars: 30 μm in lower magnification and 10 mm in higher magnification.
advantageous complements when it comes to explo-
ration of isolated phenomena. Moreover, in vitro mo -
dels are easy to use, affordable, less ethically chal-
lenged, reproducible and better controlled, and
re present a good platform for drug screening
(21–23). Hence, in vitro models of TBI are a variable
tool in studying the pathobiology beyond brain injury
and there is a need to define them more profoundly. 
Reactive astrogliosis is an event that occurs in
vivo in response to all forms of brain injury. Typical
biochemical hallmark of reactive astrogliosis is
increased expression of intermediate filament GFAP
(4, 12). However, it is important to stress that in vitro
injuries to astrocytes somewhat vary in this sense and
give rise to opposite results. For instance, results from
experiments with chemical treatments of astrocytes
(di butyryl cyclic AMP, interleukin-1b, or macrophage-
conditioned medium) suggest insignificant changes
in GFAP (12). However, the elevation of GFAP con-
tent by about 70% was estimated in a »scraping«
model of injury to astrocytes (18). It was also report-
ed that, twenty-four hours after the SW, some of the
astrocytes close to the wounding site displayed ele -
vated GFAP-immunoreactivity (17). On the contrary,
Yang et al. (15) reported no change in GFAP content
analyzed by immunoblot up to 5 days after the SW.
Our results indicate that mRNA levels for GFAP re -
main unchanged 4 hours after the SW injury to astro-
cytes. However, ICC analysis of GFAP expression re -
vealed an enhanced immunopositive signal for GFAP
in astrocytes surrounding the scratch site. More over,
astrocytes close to the injury site gained characteristic
morphological features of reactive astrocytes: hyper-
trophia and elongation of pro cesses. Similar results
were previously obtained after a mechanical stretch of
differentiated astrocytes with addition of meningeal
fibroblasts, where increases in peak of GFAP immuno -
fluorescence did not match increases in de novo
GFAP expression (24). Wanner et al. (24) contemplat-
ed that GFAP accumulation in astrocyte processes
may partially be a result of cell contraction and cyto -
skeletal fasciculation. Taken together, these results
suggest that GFAP is unreliable as a marker for astro-
cytes activation in vitro. It is also known from in vivo
models that TBI causes accumulation of CSPGs which
contribute to the formation of a barrier that prevents
axonal regeneration through the injured site (7, 25,
26). Moreover, it is thought that reactive astrocytes
are the primary source of these important inhibitory
proteins (10). Previous studies suggest that all mem-
bers of the CSPG family are upregulated after CNS
injury (27, 28), although this alteration varies in terms
of examined structure and time point after the injury
(29). Since phosphacan, neurocan and brevican have
been recognized as markers of post-injury scar forma-
tion, the main focus of this study was to estimate the
dynamics of their expression in astrocytes, four hours
after the SW injury. Our qRT-PCR data showed that
scratching of mixed astrocyte-microglial culture led to
increased expression of neurocan and phosphacan,
whereas transcript levels of brevican dropped below
control values. Furthermore, ICC analysis revealed
that all three CSPGs where expressed in astrocytes
and not in microglia. 
The most abundant mRNA transcript of herein
examined CSPGs was for neurocan. Our results indi-
cate that cultured astrocytes produce neurocan and
that the SW injury induced substantial upregulation of
neurocan mRNA, which is consistent with previous in
vitro (30) and in vivo (6, 29, 31) observations. 
Another major component of the CSPG family,
phosphacan, is highly upregulated following different
types of CNS injury in vivo (32–34). Although some
studies indicate that phosphacan is downregulated
immediately after the injury (29), we have found up-
regulation 4 hours after the SW which was consistent
with previously published results of in vitro injury in
astrocytes (24). Our ICC data revealed that both neu-
rocan and phosphacan immunoreactivity was seen in
the perinuclear area of control astrocytes. SW
induced enhanced staining in the elongated process-
es of astrocytes surrounding the scratch site, similar
to previous descriptions (24).
Although it has been confirmed both in vivo and
in vitro that astrocytes are the major source of brevi-
can (35–37), results of qRT-PCR analysis from our
cultures suggested that brevican transcript was drasti-
cally less present compared to neurocan and phos-
phacan. It is important to note that SW induced a
decrease in expression to about half of the value seen
in control. Similar drop in brevican mRNA and protein
levels below control was reported in different in vivo
models of brain (37, 38) and spinal cord injuries (39).
In conclusion, we have demonstrated that after
4 hours, the SW injury in mixed astrocyte-microglial
culture induced 1) astrocyte stellation and migration
to the injury site, 2) upregulation of phosphacan and
neurocan and downregulation of brevican in astro-
cytes, and 3) enhanced staining of GFAP in astrocytes
close to the scratch site without affecting GFAP
mRNA levels. 
Therefore, the present system may be consid-
ered as a good model of an in vitro glial scarring and
may be useful for elucidating mechanisms beyond its
formation as well as for testing potential therapeutic
approaches. 
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